SAN DIEGO — A one-time treatment with lovotibeglogene autotemcel (Lyfgenia, lovo-cel) achieved near complete resolution of severe pain crises in patients with sickle cell disease (SCD) in an analysis presented here.
Of 34 evaluable patients, 88.2% (95% CI 72.5-96.7) achieved complete resolution of all vaso-occlusive events (VOEs) and 94.1% (95% CI 80.3-99.3) experienced complete resolution of severe VOEs during a 6 to 18 month assessment period following lovo-cel infusion, reported Julie Kanter, MD, of the University of Alabama at Birmingham.
Patients who experienced any kind of acute pain event or vaso-occlusive event post-treatment experienced a reduction of at least 50% compared with baseline, as well as a reduction in hospital admissions (2.5 to 0.4) and days in hospital (15.75 to 2.20).
All 10 adolescents (≥12 years to
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : MedPageToday – https://www.medpagetoday.com/meetingcoverage/ashhematology/107776
